Categories
- Automotive
- Bearings
- Business Services
- Chemicals and Materials
- Coatings
- Company Profiles
- Consumer Goods
- Defense
- Electronics
- Energy
- Financial Services
- Food & Beverages
- Manufacturing & Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Public Sector
- Resins
- Technology
- Telecommunications and Wireless
- Vacuum Products
Popular Articles
Sorry. No data so far.
ABLYNX – Nanobodies – Turnarond on the Horizon!
US$ 140Partnering of ALX-0061 (PhI/II, Anti-IL6R, RA) with AbbVie under attractive terms (deal value of $840m/~€630m) and news flow in last one year brought back Ablynx (ABLX) and its nanobody platform’s’ potential in the limelight!
07-16 2015 Pages: 7Rituximab biosimilar
US$ 2000Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several other conditions and had $2 billion in sales in Europe last year.
07-16 2015 Pages: 45Hepatitis C Virus Infection
US$ 1000Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead’s Sofosbuvir/RBV
07-16 2015 Pages: 33Dietary Supplements: World of Opportunities In the Indian Healthcare Market
US$ 2000Increasing rate of chronic diseases has emphasized the need of Prevention over Intervention. These proactive health solutions include nutritional supplements which promise medical or health benefits and fall between the food and pharma chain – ‘Nutraceuticals’.
07-16 2015 Pages: 62New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan
US$ 4000The launch of Remicade biosimilar in Dec-2014 in the Japan pharma market demonstrated its changing regulatory environment; it is faster than U.S. in adapting to biosimilar use. After nine years of continuous efforts by the JP government to promote increased use of generics
07-16 2015 Pages: 65Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
US$ 3000Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing the life expectancy WW.
07-16 2015 Pages: 98Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease
US$ 3000While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes,
07-16 2015 Pages: 82Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain
US$ 3000Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined.
07-16 2015 Pages: 65
